PURPOSE: [(124)I]m-iodobenzylguanidine ((124)I-mIBG) provides a quantitative tool for pretherapy tumor imaging and dosimetry when performed before [(131)I]m-iodobenzylguanidine ((131)I-mIBG) targeted radionuclide therapy of neuroblastoma. (124)I (T (1/2) = 4.2 days) has a comparable half-life to that of (131)I (T (1/2) = 8.02 days) and can be imaged by positron emission tomography (PET) for accurate quantification of the radiotracer distribution. We estimated expected radiation dose in tumors from (131)I-mIBG therapy using (124)I-mIBG microPET/CT imaging data in a murine xenograft model of neuroblastoma transduced to express high levels of the human norepinephrine transporter (hNET). PROCEDURES: In order to enhance mIBG uptake for in vivo imaging and therapy, NB 1691-luciferase (NB1691) human neuroblastoma cells were engineered to express high levels of hNET protein by lentiviral transduction (NB1691-hNET). Both NB1691 and NB1691-hNET cells were implanted subcutaneously and into renal capsules in athymic mice. (124)I-mIBG (4.2-6.5 MBq) was administered intravenously for microPET/CT imaging at 5 time points over 95 h (0.5, 3-5, 24, 48, and 93-95 h median time points). In vivo biodistribution data in normal organs, tumors, and whole-body were collected from reconstructed PET images corrected for photon attenuation using the CT-based attenuation map. Organ and tumor dosimetry were determined for (124)I-mIBG. Dose estimates for (131)I-mIBG were made, assuming the same in vivo biodistribution as (124)I-mIBG. RESULTS: All NB1691-hNET tumors had significant uptake and retention of (124)I-mIBG, whereas unmodified NB1691 tumors did not demonstrate quantifiable mIBG uptake in vivo, despite in vitro uptake. (124)I-mIBG with microPET/CT provided an accurate three-dimensional tool for estimating the radiation dose that would be delivered with (131)I-mIBG therapy. For example, in our model system, we estimated that the administration of (131)I-mIBG in the range of 52.8-206 MBq would deliver 20 Gy to tumors. CONCLUSIONS: The overexpression of hNET was found to be critical for (124)I-mIBG uptake and retention in vivo. The quantitative (124)I-mIBG PET/CT is a promising new tool to predict tumor radiation doses with (131)I-mIBG therapy of neuroblastoma. This methodology may be applied to tumor dosimetry of (131)I-mIBG therapy in human subjects using (124)I-mIBG pretherapy PET/CT data.
PURPOSE: [(124)I]m-iodobenzylguanidine ((124)I-mIBG) provides a quantitative tool for pretherapy tumor imaging and dosimetry when performed before [(131)I]m-iodobenzylguanidine ((131)I-mIBG) targeted radionuclide therapy of neuroblastoma. (124)I (T (1/2) = 4.2 days) has a comparable half-life to that of (131)I (T (1/2) = 8.02 days) and can be imaged by positron emission tomography (PET) for accurate quantification of the radiotracer distribution. We estimated expected radiation dose in tumors from (131)I-mIBG therapy using (124)I-mIBG microPET/CT imaging data in a murine xenograft model of neuroblastoma transduced to express high levels of the humannorepinephrine transporter (hNET). PROCEDURES: In order to enhance mIBG uptake for in vivo imaging and therapy, NB 1691-luciferase (NB1691) humanneuroblastoma cells were engineered to express high levels of hNET protein by lentiviral transduction (NB1691-hNET). Both NB1691 and NB1691-hNET cells were implanted subcutaneously and into renal capsules in athymic mice. (124)I-mIBG (4.2-6.5 MBq) was administered intravenously for microPET/CT imaging at 5 time points over 95 h (0.5, 3-5, 24, 48, and 93-95 h median time points). In vivo biodistribution data in normal organs, tumors, and whole-body were collected from reconstructed PET images corrected for photon attenuation using the CT-based attenuation map. Organ and tumor dosimetry were determined for (124)I-mIBG. Dose estimates for (131)I-mIBG were made, assuming the same in vivo biodistribution as (124)I-mIBG. RESULTS: All NB1691-hNETtumors had significant uptake and retention of (124)I-mIBG, whereas unmodified NB1691 tumors did not demonstrate quantifiable mIBG uptake in vivo, despite in vitro uptake. (124)I-mIBG with microPET/CT provided an accurate three-dimensional tool for estimating the radiation dose that would be delivered with (131)I-mIBG therapy. For example, in our model system, we estimated that the administration of (131)I-mIBG in the range of 52.8-206 MBq would deliver 20 Gy to tumors. CONCLUSIONS: The overexpression of hNET was found to be critical for (124)I-mIBG uptake and retention in vivo. The quantitative (124)I-mIBG PET/CT is a promising new tool to predict tumor radiation doses with (131)I-mIBG therapy of neuroblastoma. This methodology may be applied to tumor dosimetry of (131)I-mIBG therapy in human subjects using (124)I-mIBG pretherapy PET/CT data.
Authors: J Treuner; U Feine; D Niethammer; W Müller-Schaumburg; J Meinke; E Eibach; R Dopfer; T Klingebiel; S Grumbach Journal: Lancet Date: 1984-02-11 Impact factor: 79.321
Authors: John A Barrett; John L Joyal; Shawn M Hillier; Kevin P Maresca; Frank J Femia; James F Kronauge; Marie Boyd; Robert J Mairs; John W Babich Journal: Cancer Biother Radiopharm Date: 2010-06 Impact factor: 3.099
Authors: Mark N Gaze; Yen-Ch'ing Chang; Glenn D Flux; Rob J Mairs; Frank H Saran; Simon T Meller Journal: Cancer Biother Radiopharm Date: 2005-04 Impact factor: 3.099
Authors: Katherine K Matthay; Jessica C Tan; Judith G Villablanca; Gregory A Yanik; Janet Veatch; Benjamin Franc; Eilish Twomey; Biljana Horn; C Patrick Reynolds; Susan Groshen; Robert C Seeger; John M Maris Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn Journal: Br J Cancer Date: 2010-04-27 Impact factor: 7.640
Authors: Sean Carlin; Rob J Mairs; Anthony G McCluskey; Deborah A Tweddle; Alan Sprigg; Christine Estlin; Julian Board; Rani E George; Caroline Ellershaw; Andrew D J Pearson; John Lunec; Paolo G Montaldo; Mirco Ponzoni; Berthe L van Eck-Smit; Cees A Hoefnagel; Marieke D van den Brug; Godelieve A M Tytgat; Huib N Caron Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Katherine K Matthay; Gregory Yanik; Julia Messina; Alekist Quach; John Huberty; Su-Chun Cheng; Janet Veatch; Robert Goldsby; Patricia Brophy; Leslie S Kersun; Randall A Hawkins; John M Maris Journal: J Clin Oncol Date: 2007-03-20 Impact factor: 44.544
Authors: Paxton V Dickson; Blair Hamner; Catherine Y C Ng; Marshall M Hall; Junfang Zhou; Phillip W Hargrove; M Beth McCarville; Andrew M Davidoff Journal: J Pediatr Surg Date: 2007-07 Impact factor: 2.545
Authors: Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz Journal: J Nucl Med Date: 2019-03-29 Impact factor: 10.057
Authors: Youngho Seo; Yoonsuk Huh; Shih-Ying Huang; J Miguel Hernandez-Pampaloni; Randall A Hawkins; W Clay Gustafson; Kieuhoa T Vo; Katherine K Matthay Journal: Med Phys Date: 2019-03-12 Impact factor: 4.071
Authors: Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto Journal: J Nucl Med Date: 2017-07-26 Impact factor: 10.057